Angina patients hit with a new shortage as replacement product supply now in peril
There are now fears for the supply of a product arranged as a replacement for an existing treatment that was suffering production issues.
The TGA is informing patients and health practitioners that it now “anticipates that there will be a shortage of the alternative product 600 mcg (0.6 mg) Nitrostat tablets”.
The tablets had been arranged as an alternative to glyceryl trinitrate (GTN) tablets, sold in Australia under the brand names Anginine and Lycinate, for treating acute angina pectoris (chest or heart pain caused by coronary heart disease).
Last year there were reports that a new formulation of GTN tablets for sublingual use were taking longer than usual to disintegrate and were more difficult to break in half, leading to a search for an alternative.
However, the TGA says the 300 mcg (0.3 mg) Nitrostat tablets are not expected to be in short supply and two 300 mcg tablets can be taken as an alternative to one 600 mcg tablet.
Additionally, supplier Pfizer Australia says it is working to make more units of the 600 mcg tablets available as soon as possible.
Click here for more information on both shortages